Evidence map›Paper›PMID 38698370›Full record

ArticleBMC oral health2024

F. Nucleatum enhances oral squamous cell carcinoma proliferation via E-cadherin/β-Catenin pathway.

Zhengrui Li, Yuan Liu, Xufeng Huang, Qi Wang, Rao Fu, Xutao Wen, Ji'an Liu, Ling Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC oral health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Review
  2. Review
  3. Medicina (Kaunas, Lithuania) · 2026
    Article
  4. Article
  5. Article
  6. Microbiota in cancer: current understandings and future perspectives.Signal transduction and targeted therapy · 2026
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhengrui Li *Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, No. 639, Zhizaoju Road, Huangpu District, Shanghai, 200011, China.
Yuan Liu *Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, No. 639, Zhizaoju Road, Huangpu District, Shanghai, 200011, China.
Xufeng Huang *Faculty of Dentistry, University of Debrecen, Debrecen, Hungary. huangxufeng@mailbox.unideb.hu.
Qi WangJiangsu University, Zhenjiang, China.
Rao FuDepartment of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, No. 639, Zhizaoju Road, Huangpu District, Shanghai, 200011, China.
Xutao WenDepartment of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, No. 639, Zhizaoju Road, Huangpu District, Shanghai, 200011, China.
Ji'an LiuDepartment of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, No. 639, Zhizaoju Road, Huangpu District, Shanghai, 200011, China.
Ling ZhangDepartment of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, No. 639, Zhizaoju Road, Huangpu District, Shanghai, 200011, China. topgun1128@163.com.

Funding

Medical Engineering Cross Foundation of Shanghai Jiao Tong University YG2015MS06National Natural Science Foundation of China 81771127Natural Science Foundation of Xinjiang Uygur Autonomous Region 2022D01C15Seed Foundation of the Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine JYZZ196Stomatology Clinical Research Project of Nation Clinical Center forOral Disease NCRCO202330
6 · The paper itself

Abstract

backgroundFusobacterium nucleatum (F. nucleatum) is a microbial risk factor whose presence increases the risk of oral squamous cell carcinoma (OSCC) progression. However, whether it can promote the proliferation of OSCC cells remains unknown.

methodsIn this study, we investigated F. nucleatum effect on OSCC cell proliferation using in vitro and in vivo experiments.

resultsOur results showed that F. nucleatum promoted OSCC cell proliferation, doubling the cell count after 72 h (CCK-8 assay). Cell cycle analysis revealed G2/M phase arrest. F. nucleatum interaction with CDH1 triggered phosphorylation, upregulating downstream protein β-catenin and activating cyclinD1 and Myc. Notably, F. nucleatum did not affect noncancerous cells, unrelated to CDH1 expression levels in CAL27 cells. Overexpression of phosphorylated CDH1 in 293T cells did not upregulate β-catenin and cycle-related genes. In vivo BALB/c nude experiments showed increased tumor volume and Ki-67 proliferation index after F. nucleatum intervention.

conclusionOur study suggests that F. nucleatum promotes OSCC cell proliferation through the CDH1/β-catenin pathway, advancing our understanding of its role in OSCC progression and highlighting its potential as a therapeutic target.

Indexed as

beta CateninCadherinsCarcinoma, Squamous CellCell ProliferationFusobacterium nucleatumMice, Inbred BALB CMice, NudeMouth NeoplasmsAnimalsAntigens, CDCell Line, TumorHumansMiceSignal TransductionAntigens, CDbeta CateninCadherinsCDH1 protein, humanCDH1(E-Cadherin)Cell cycleCell proliferationFusobacterium nucleatumOral squamous cell carcinomaPhosphorylationβ-catenin

Identifiers

PMID38698370
PMCPMC11064238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.